Provectus Biopharmaceutica-APVCT
13F holders, Q2 2026 (June 30)4holders −2
0new positions
2sold out
$0.07avg. 13F price*
At the end of Q2 2026, 4 institutions reported holding Provectus Biopharmaceutica-A (PVCT) in their 13F filings, down 2 from Q1 2026. 0 opened new positions and 2 sold out. The largest holders were Home Federal Bank of Tennessee ($7K), Atlas Wealth LLC ($1K) and Financial Symmetry Inc ($707).
- Company
- Provectus Biopharmaceutica-A
- CUSIP
- 74373P108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 2 | $4K |
All 13F filers, Q1 2026 → Q2 2026: 72,600 shares sold, net −72,600 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Home Federal Bank of Tennessee | 0.00% | No change | 100,000 | $7K |
| Atlas Wealth LLC | 0.00% | No change | 19,620 | $1K |
| Financial Symmetry Inc | 0.00% | No change | 10,191 | $707 |
| Huntington National Bank | 0.00% | No change | 1 | $0 |
"% of holder's portfolio" is PVCT's weight in each manager's 13F, not the share of Provectus Biopharmaceutica-A the manager owns.